Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Welcome once again to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we get started, let me jump into the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I'm happy to introduce in the next session from Arcutis, CEO, Frank Watanabe; CFO, Scott Burrows; CCO, Ken Lock; and CMO, Patrick Burnett.
Questions & Answers
I guess if you could start out Arcutis is late-stage dermatology company. You have one drug that already produced Phase III results and other -- some other Phase III trials that are in the works. Could you talk about the top level vision
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
